To investigate the differences in therapeutic outcome when targeting Rac1P29S+ MC703-FSG tumors with either Rac1- or Rac2-specific T cells, we monitored the human TCR-transduced HHD+ T cells after transfer into tumor-bearing mice in the second experiment (Figure 3D and Supplementary Figures 3A, B). The gene discussed is RAC1; the disease is neoplasm.